Enhanced Immunity toPlasmodium falciparumCircumsporozoite Protein (PfCSP) by UsingSalmonella entericaSerovar Typhi Expressing PfCSP and a PfCSP-Encoding DNA Vaccine in a Heterologous Prime-Boost Strategy
Open Access
- 1 August 2007
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 75 (8) , 3769-3779
Abstract
TwoSalmonella entericaserovar Typhi strains that express and export a truncated version ofPlasmodium falciparumcircumsporozoite surface protein (tCSP) fused toSalmonellaserovar TyphicytolysinA(ClyA) were constructed as a first step in the development of a preerythrocytic malaria vaccine. Synthetic codon-optimized genes (t-csp1and t-csp2), containing immunodominant B- and T-cell epitopes present in nativeP. falciparumcircumsporozoite surface protein (PfCSP), were fused in frame to the carboxyl terminus of the ClyA gene (clyA::t-csp) in genetically stabilized expression plasmids. Expression and export of ClyA-tCSP1 and ClyA-tCSP2 bySalmonellaserovar Typhi vaccine strain CVD 908-htrAwere demonstrated by immunoblotting of whole-cell lysates and culture supernatants. The immunogenicity of these constructs was evaluated using a “heterologous prime-boost” approach consisting of mucosal priming withSalmonellaserovar Typhi expressing ClyA-tCSP1 and ClyA-tCSP2, followed by parenteral boosting with PfCSP DNA vaccines pVR2510 and pVR2571. Mice primed intranasally on days 0 and 28 with CVD 908-htrA(pSEC10tcsp2) and boosted intradermally on day 56 with PfCSP DNA vaccine pVR2571 induced high titers of serum NANP immunoglobulin G (IgG) (predominantly IgG2a); no serological responses to DNA vaccination were observed in the absence ofSalmonellaserovar Typhi-PfCSP priming. Mice primed withSalmonellaserovar Typhi expressing tCSP2 and boosted with PfCSP DNA also developed high frequencies of gamma interferon-secreting cells, which surpassed those produced by PfCSP DNA in the absence of priming. A prime-boost regimen consisting of mucosal delivery of PfCSP exported from aSalmonella-based live-vector vaccine followed by a parenteral PfCSP DNA boosting is a promising strategy for the development of a live-vector-based malaria vaccine.Keywords
This publication has 59 references indexed in Scilit:
- Oral Administration of a Salmonella enterica -Based Vaccine Expressing Bacillus anthracis Protective Antigen Confers Protection against Aerosolized B. anthracisInfection and Immunity, 2007
- Adaptation of the Endogenous Salmonella enterica Serovar Typhi clyA -Encoded Hemolysin for Antigen Export Enhances the Immunogenicity of Anthrax Protective Antigen Domain 4 Expressed by the Attenuated Live-Vector Vaccine Strain CVD 908- htrAInfection and Immunity, 2004
- Recombinant Salmonella enterica serovar Typhi in a prime-boost strategyVaccine, 2004
- Phase 1 Evaluation of 3 Highly Immunogenic Prime‐Boost Regimens, Including a 12‐Month Reboosting Vaccination, for Malaria Vaccination in Gambian MenThe Journal of Infectious Diseases, 2004
- Reduced immunogenicity of DNA vaccine plasmids in mixturesGene Therapy, 2004
- Parasite-specific immunoglobulin isotypes during lethal and non-lethal murine malaria infectionsParasitology Research, 2002
- Protection of Rhesus Macaques against LethalPlasmodium knowlesiMalaria by a Heterologous DNA Priming and Poxvirus Boosting Immunization RegimenInfection and Immunity, 2002
- Regulation of immunity to malaria: valuable lessons learned from murine modelsParasitology Today, 1995
- Molecular analysis of the association of HLA-B53 and resistance to severe malariaNature, 1992
- Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoite of the Human Malaria Parasite Plasmodium falciparumScience, 1984